Syros Pharmaceuticals Inc. (Nasdaq: SYRS) presented disappointing preclinical data from an ongoing Phase 1 clinical trial of SY-1365. The stock price plunged $3.92 to close at $8.45.
Syros Pharmaceuticals presents disappointing data
December 11, 2017 at 17:12 PM EST
